GlaxoSmithKline teams with Vir Biotechnology to develop coronavirus vaccine, treatments

The Business Journals | April 06, 2020

GlaxoSmithKline and Vir Biotechnology Inc. said Monday they have signed a binding coronavirus research and development agreement. As part of the agreement, GlaxoSmithKline (NYSE: GSK) will invest $250 million in Vir (NASDAQ: VIR). GlaxoSmithKline, based in London, has large operations in Philadelphia and Montgomery County. Vir is based in San Francisco. Shares in Vir jumped almost 27% to close at $36.70 Monday. GSK's stock price finished up 2% to $37.91. The collaboration will seek to use Vir’s proprietary monoclonal antibody platform technology to accelerate the development of existing anti-viral antibodies, and to identify new ones, that could be used as a vaccine or therapy to help address the COVID-19 pandemic and future outbreaks.

Spotlight

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Spotlight

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Related News

CELL AND GENE THERAPY

Cellares and Poseida Therapeutics Join Forces to Speed Up Cell Therapy Manufacturing

Cellares Corporation | July 16, 2021

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Center as the third entity to join Cellares' EAPP. Cellares launched the EAPP in 2020 to provide participants awareness and early access to Cellares' Cell Shuttle, a next-generation cell therapy manufacturing platform that enables closed, automated, and scalable cell therapy production. Poseida's involvement in the initiative adds to the Cell Shuttle's development, range of usage, and applicability by providing insight and experience in manufacturing processes for various autologous and allogeneic cell therapies. Poseida is presently testing two autologous CAR-T product candidates in the clinic: P-BCMA-101 for relapsed/refractory multiple myeloma and P-PSMA-101 for metastatic castrate-resistant prostate cancer. The firm, which completed an initial public offering in July 2020, is also developing off-the-shelf versions of these treatments and TCR-T, anti-c-kit CAR-T, induced pluripotent stem cells (iPSCs), genetically modified hematopoietic stem cells (HSCs), and NK cells. In addition, Carl June, M.D., an immunotherapy pioneer and renowned oncologist who advised Cellares on creating the Cell Shuttle has just joined Poseida's Immuno-Oncology Scientific Advisory Board. Poseida will assess the Cell Shuttle prototypes and give statistics and written comments related to their function and performance as part of Cellares' EAPP. In addition, user studies will be conducted to assess the Cell Shuttle's hardware and software, product requirements, release criteria, and process processes to ensure product-market fit. About The Cell Shuttle The Cell Shuttle is a flexible and scalable automated and closed end-to-end production solution that allows clients to execute the precise procedures required for their cell therapy. Compared to presently existing cell therapy manufacturing methods, this next-generation platform allows for a threefold decrease in process failure rates and the ability to produce 10+ patient doses in parallel, improving manufacturing scalability by order of magnitude. For most processes, this will reduce per-patient manufacturing costs by up to 70%. About Cellares Corporation Cellares is rethinking cell therapy manufacturing and accelerating access to life-saving cell therapies. The business is working on a one-of-a-kind approach to solving the difficulties of generating cell therapies that are cheaper and broadly accessible to people in need. Cellares' proprietary platform, the Cell Shuttle, eliminates the need for biopharma companies, academic research centers, and CDMOs to choose between a manufacturing platform that is semi-automated but lacks workflow flexibility or one that provides customization but lacks the end-to-end automation required to manufacture at scale. The business is based in South San Francisco, California.

Read More

Aegle Therapeutics Receives Rare Pediatric Disease Designation from the FDA for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerative healing factors to diseased and damaged tissue. "The FDA's grant of Rare Pediatric Disease designation following its earlier grant of Fast Track Designation to AGLE-102 for DEB underscores the significant unmet medical need of children and adults living with this debilitating disease. AGLE-102 has the potential to be the first multifaceted approach to treat this rare patient population," said Shelley Hartman, CEO of Aegle Therapeutics. The FDA grants Rare Pediatric Disease designation for diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the U.S. If Aegle's new drug application ("NDA") for DEB is approved, Aegle may receive a priority review voucher from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application or may be sold to another company for their programs.

Read More

RESEARCH

Vipergen Collaborates with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs

Vipergen ApS, Anavo Therapeutics | May 18, 2021

Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen's novel solutions to DNA-encoded libraries are useful components for ramping up our patented drug development activities against a chosen portfolio of innovative goals," said Anavo CEO Birgit Zech, Ph.D. "We are excited to collaborate with Vipergen to kick-start Anavo's proprietary drug development activities as we strive to create a comprehensive and secure platform for phosphatase drug discovery against all valuable targets in the space." "We are delighted to have been chosen by Anavo, a new company focusing on understanding the full therapeutic potential of human phosphatase biology in the development of new cancer therapies," said Nils Hansen, Ph.D., Chief Executive Officer of Vipergen. "Phosphatases are a rich target space that has been thought to be impenetrable for decades. We are excited to use our DNA-encoded library technology to quickly produce high-quality hits and leads as part of Anavo's comprehensive approach to finding and improving small-molecule phosphatase activity modulators." About Vipergen ApS Vipergen is the world's largest supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technology, as well as the first and only organization capable of screening DELs within a living cell. Vipergen's patented portfolio of cutting-edge DEL technologies is made accessible by funded discovery collaborations with leading pharmaceutical and biotechnology firms, including top pharmaceutical companies in the United States, Europe, and Japan.

Read More